niclosamide has been researched along with Cancer of Mouth in 4 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral Squamous Cell Carcinoma (OSCC) is one of the major causes of cancer related deaths worldwide." | 1.51 | CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma. ( Pindiprolu, SH; Pindiprolu, SKSS, 2019) |
| "Niclosamide is an oral anti-helminthic drug used to treat human tapeworms." | 1.48 | Niclosamide acts as a new inhibitor of vasculogenic mimicry in oral cancer through upregulation of miR-124 and downregulation of STAT3. ( Han, Z; Li, X; Ma, Z; Wang, Y; Wen, Y; Yang, Z, 2018) |
| "Niclosamide is an oral chlorinated salicylanilide antihelminthic agent with potential anticancer activity suggested in several cancer types, however, its anticancer action and likely molecular mechanism in malignant oral cells remain unclear." | 1.48 | The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC. ( Chen, XY; Fu, LQ; Wang, LH; Xu, M; Yang, F, 2018) |
| "Niclosamide is an oral anti-helminthic drug, its anti-cancer effect has been reported in recent years." | 1.46 | Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. ( Ding, R; Han, Z; Li, X; Ma, Z; Wang, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 2 |
| Ding, R | 1 |
| Han, Z | 2 |
| Ma, Z | 2 |
| Wang, Y | 2 |
| Yang, Z | 1 |
| Wen, Y | 1 |
| Wang, LH | 1 |
| Xu, M | 1 |
| Fu, LQ | 1 |
| Chen, XY | 1 |
| Yang, F | 1 |
| Pindiprolu, SH | 1 |
| Pindiprolu, SKSS | 1 |
4 other studies available for niclosamide and Cancer of Mouth
| Article | Year |
|---|---|
Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells.
Topics: Antinematodal Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Pr | 2017 |
Niclosamide acts as a new inhibitor of vasculogenic mimicry in oral cancer through upregulation of miR-124 and downregulation of STAT3.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regul | 2018 |
The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Topics: Aldehyde Dehydrogenase; Anthelmintics; Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Sq | 2018 |
CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma.
Topics: AC133 Antigen; Apoptosis; Carcinoma, Squamous Cell; Drug Carriers; Drug Delivery Systems; Epithelial | 2019 |